<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>cytarabine</title><link>http://www.unboundmedicine.com/medline/ebm/research/cytarabine</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19917845/full_citation/Immunochemotherapy_and_Autologous_Stem_Cell_Transplantation_for_Untreated_Patients_With_Mantle_Cell_Lymphoma:_CALGB_59909_</link><description>Damon LE, Johnson JL, Niedzwiecki D, et al. <br/><span class="title">Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of clinical oncology : official journal of the American Society of Clinical Oncology">J Clin Oncol 2009 Nov 16.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19917845/abstract/Immunochemotherapy_and_Autologous_Stem_Cell_Transplantation_for_Untreated_Patients_With_Mantle_Cell_Lymphoma:_CALGB_59909_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19917845/full_citation/Immunochemotherapy_and_Autologous_Stem_Cell_Transplantation_for_Untreated_Patients_With_Mantle_Cell_Lymphoma:_CALGB_59909_">Full Citation</a> | <a href="http://www.jco.org/cgi/pmidlookup%3fview=long%26amp;pmid=19917845">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19917845/Immunochemotherapy_and_Autologous_Stem_Cell_Transplantation_for_Untreated_Patients_With_Mantle_Cell_Lymphoma:_CALGB_59909_">Find Related Articles</a> </description></item><item><title>Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).</title><link>http://www.unboundmedicine.com/medline/ebm/record/19914958/full_citation/Long_term_follow_up_of_an_age_adapted_C5R_protocol_followed_by_radiotherapy_in_99_newly_diagnosed_primary_CNS_lymphomas:_a_prospective_multicentric_phase_II_study_of_the_Groupe_d'Etude_des_Lymphomes_de_l'Adulte__GELA__</link><description>Ghesquières H, Ferlay C, Sebban C, et al. <br/><span class="title">Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). [JOURNAL ARTICLE]</span><br/><span class="source" title="Annals of oncology : official journal of the European Society for Medical Oncology / ESMO">Ann Oncol 2009 Nov 18.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19914958/abstract/Long_term_follow_up_of_an_age_adapted_C5R_protocol_followed_by_radiotherapy_in_99_newly_diagnosed_primary_CNS_lymphomas:_a_prospective_multicentric_phase_II_study_of_the_Groupe_d'Etude_des_Lymphomes_de_l'Adulte__GELA__">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19914958/full_citation/Long_term_follow_up_of_an_age_adapted_C5R_protocol_followed_by_radiotherapy_in_99_newly_diagnosed_primary_CNS_lymphomas:_a_prospective_multicentric_phase_II_study_of_the_Groupe_d'Etude_des_Lymphomes_de_l'Adulte__GELA__">Full Citation</a> | <a href="http://annonc.oxfordjournals.org/cgi/pmidlookup%3fview=long%26amp;pmid=19914958">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19914958/Long_term_follow_up_of_an_age_adapted_C5R_protocol_followed_by_radiotherapy_in_99_newly_diagnosed_primary_CNS_lymphomas:_a_prospective_multicentric_phase_II_study_of_the_Groupe_d'Etude_des_Lymphomes_de_l'Adulte__GELA__">Find Related Articles</a> </description></item><item><title>Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19911860/full_citation/Azacitidine:_a_review_of_its_use_in_higher_risk_myelodysplastic_syndromes/acute_myeloid_leukaemia_</link><description>Keating GM <br/><span class="title">Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. [Journal Article]</span><br/><span class="source" title="Drugs">Drugs 2009; 69(17):2501-18.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19911860/abstract/Azacitidine:_a_review_of_its_use_in_higher_risk_myelodysplastic_syndromes/acute_myeloid_leukaemia_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19911860/full_citation/Azacitidine:_a_review_of_its_use_in_higher_risk_myelodysplastic_syndromes/acute_myeloid_leukaemia_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19911860/Azacitidine:_a_review_of_its_use_in_higher_risk_myelodysplastic_syndromes/acute_myeloid_leukaemia_">Find Related Articles</a> </description></item><item><title>Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19899957/full_citation/Ethanol_injection_method_for_hydrophilic_and_lipophilic_drug_loaded_liposome_preparation_</link><description>Jaafar-Maalej C, Diab R, Andrieu V, et al. <br/><span class="title">Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of liposome research">J Liposome Res 2009 Nov 9.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19899957/abstract/Ethanol_injection_method_for_hydrophilic_and_lipophilic_drug_loaded_liposome_preparation_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19899957/full_citation/Ethanol_injection_method_for_hydrophilic_and_lipophilic_drug_loaded_liposome_preparation_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19899957/Ethanol_injection_method_for_hydrophilic_and_lipophilic_drug_loaded_liposome_preparation_">Find Related Articles</a> </description></item><item><title>Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19898504/full_citation/Fotemustine_plus_etoposide_cytarabine_and_melphalan__FEAM__as_a_new_conditioning_regimen_for_lymphoma_patients_undergoing_auto_SCT:_a_multicenter_feasibility_study_</link><description>Musso M, Scalone R, Marcacci G, et al. <br/><span class="title">Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. [JOURNAL ARTICLE]</span><br/><span class="source" title="Bone marrow transplantation">Bone Marrow Transplant 2009 Nov 9.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19898504/abstract/Fotemustine_plus_etoposide_cytarabine_and_melphalan__FEAM__as_a_new_conditioning_regimen_for_lymphoma_patients_undergoing_auto_SCT:_a_multicenter_feasibility_study_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19898504/full_citation/Fotemustine_plus_etoposide_cytarabine_and_melphalan__FEAM__as_a_new_conditioning_regimen_for_lymphoma_patients_undergoing_auto_SCT:_a_multicenter_feasibility_study_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19898504/Fotemustine_plus_etoposide_cytarabine_and_melphalan__FEAM__as_a_new_conditioning_regimen_for_lymphoma_patients_undergoing_auto_SCT:_a_multicenter_feasibility_study_">Find Related Articles</a> </description></item><item><title>Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19890398/full_citation/Oncogenic_RAS_Enables_DNA_Damage__and_p53_Dependent_Differentiation_of_Acute_Myeloid_Leukemia_Cells_in_Response_to_Chemotherapy_</link><description>Meyer M, Rübsamen D, Slany R, et al. <br/><span class="title">Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy. [Journal Article]</span><br/><span class="source" title="PloS one">PLoS One 2009; 4(11):e7768.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19890398/abstract/Oncogenic_RAS_Enables_DNA_Damage__and_p53_Dependent_Differentiation_of_Acute_Myeloid_Leukemia_Cells_in_Response_to_Chemotherapy_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19890398/full_citation/Oncogenic_RAS_Enables_DNA_Damage__and_p53_Dependent_Differentiation_of_Acute_Myeloid_Leukemia_Cells_in_Response_to_Chemotherapy_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19890398/Oncogenic_RAS_Enables_DNA_Damage__and_p53_Dependent_Differentiation_of_Acute_Myeloid_Leukemia_Cells_in_Response_to_Chemotherapy_">Find Related Articles</a> </description></item><item><title>Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19889622/full_citation/Salvage_chemotherapy_with_alternating_MINE_ESHAP_regimen_in_relapsed_or_refractory_Hodgkin's_lymphoma_followed_by_autologous_stem_cell_transplantation_</link><description>Fernández de Larrea C, Martínez C, Gaya A, et al. <br/><span class="title">Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. [JOURNAL ARTICLE]</span><br/><span class="source" title="Annals of oncology : official journal of the European Society for Medical Oncology / ESMO">Ann Oncol 2009 Nov 4.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19889622/abstract/Salvage_chemotherapy_with_alternating_MINE_ESHAP_regimen_in_relapsed_or_refractory_Hodgkin's_lymphoma_followed_by_autologous_stem_cell_transplantation_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19889622/full_citation/Salvage_chemotherapy_with_alternating_MINE_ESHAP_regimen_in_relapsed_or_refractory_Hodgkin's_lymphoma_followed_by_autologous_stem_cell_transplantation_">Full Citation</a> | <a href="http://annonc.oxfordjournals.org/cgi/pmidlookup%3fview=long%26amp;pmid=19889622">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19889622/Salvage_chemotherapy_with_alternating_MINE_ESHAP_regimen_in_relapsed_or_refractory_Hodgkin's_lymphoma_followed_by_autologous_stem_cell_transplantation_">Find Related Articles</a> </description></item><item><title>Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19884541/full_citation/Comparison_of_Neurocognitive_Functioning_in_Children_Previously_Randomly_Assigned_to_Intrathecal_Methotrexate_Compared_With_Triple_Intrathecal_Therapy_for_the_Treatment_of_Childhood_Acute_Lymphoblastic_Leukemia_</link><description>Kadan-Lottick NS, Brouwers P, Breiger D, et al. <br/><span class="title">Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of clinical oncology : official journal of the American Society of Clinical Oncology">J Clin Oncol 2009 Nov 2.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19884541/abstract/Comparison_of_Neurocognitive_Functioning_in_Children_Previously_Randomly_Assigned_to_Intrathecal_Methotrexate_Compared_With_Triple_Intrathecal_Therapy_for_the_Treatment_of_Childhood_Acute_Lymphoblastic_Leukemia_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19884541/full_citation/Comparison_of_Neurocognitive_Functioning_in_Children_Previously_Randomly_Assigned_to_Intrathecal_Methotrexate_Compared_With_Triple_Intrathecal_Therapy_for_the_Treatment_of_Childhood_Acute_Lymphoblastic_Leukemia_">Full Citation</a> | <a href="http://www.jco.org/cgi/pmidlookup%3fview=long%26amp;pmid=19884541">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19884541/Comparison_of_Neurocognitive_Functioning_in_Children_Previously_Randomly_Assigned_to_Intrathecal_Methotrexate_Compared_With_Triple_Intrathecal_Therapy_for_the_Treatment_of_Childhood_Acute_Lymphoblastic_Leukemia_">Find Related Articles</a> </description></item><item><title>["Squalenoylation": a new approach to the design of anticancer and antiviral nanomedicines]</title><link>http://www.unboundmedicine.com/medline/ebm/record/19883017/full_citation/["Squalenoylation":_a_new_approach_to_the_design_of_anticancer_and_antiviral_nanomedicines]</link><description>Couvreur P <br/><span class="title">["Squalenoylation": a new approach to the design of anticancer and antiviral nanomedicines] [English Abstract, Journal Article]</span><br/><span class="source" title="">Bull Acad Natl Med 2009 Mar; 193(3):663-73; discussion 673-4.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19883017/abstract/[&#34;Squalenoylation&#34;:_a_new_approach_to_the_design_of_anticancer_and_antiviral_nanomedicines]">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19883017/full_citation/[&#34;Squalenoylation&#34;:_a_new_approach_to_the_design_of_anticancer_and_antiviral_nanomedicines]">Full Citation</a></description></item><item><title>Microencapsulation of cytarabine using poly(ethylene glycol)-poly(epsilon-caprolactone) diblock copolymers as surfactant agents.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19877831/full_citation/Microencapsulation_of_cytarabine_using_poly_ethylene_glycol__poly_epsilon_caprolactone__diblock_copolymers_as_surfactant_agents_</link><description>Diab R, Hamoudeh M, Boyron O, et al. <br/><span class="title">Microencapsulation of cytarabine using poly(ethylene glycol)-poly(epsilon-caprolactone) diblock copolymers as surfactant agents. [JOURNAL ARTICLE]</span><br/><span class="source" title="Drug development and industrial pharmacy">Drug Dev Ind Pharm 2009 Oct 30.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19877831/abstract/Microencapsulation_of_cytarabine_using_poly_ethylene_glycol__poly_epsilon_caprolactone__diblock_copolymers_as_surfactant_agents_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19877831/full_citation/Microencapsulation_of_cytarabine_using_poly_ethylene_glycol__poly_epsilon_caprolactone__diblock_copolymers_as_surfactant_agents_">Full Citation</a></description></item></channel></rss>